. . . "Humans and other mammals"@en . "Chlorprothixene blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis."@en . . . . . . . . "Sprague, J.M. and Engelhardt, E.L.; US. Patent 2,951,082; August 30, 1960; assigned to Merck & Co., Inc. Schlapfer, R. and Spiegelberg, H.; US. Patent 3,115,502; December 24,1963; assigned to Hoffmann-LaRoche Inc."@en . . . "approved"@en . "SID11110647"@en . . . "Chlorprothixen"@en . "SID4253130"@en . . "Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors."@en . " "@en . . "113-59-7"@en . "Chlothixen"@en . . . . . "For treatment of psychotic disorders (e.g. schizophrenia) and of acute mania occuring as part of bipolar disorders."@en . . "Chlorprotixene"@en . "SID50108484"@en . . "8 to 12 hours"@en . "Chlorprotixine"@en . "Avoid alcohol."@en . . . "Chlorprothixine"@en . "Chlorprothixene"@en . . "withdrawn"@en . . . . "Incomplete bioavailability."@en . . . . "Take with food to reduce irritation."@en . . . "Symptoms of overdose include difficulty in breathing (severe), dizziness (severe), drowsiness (severe), muscle trembling, jerking, stiffness, or uncontrolled movements (severe), small pupils, unusual excitement, and unusual tiredness or weakness (severe)."@en . . . "Chlorprotixen"@en . "SID144203583"@en . . . . . "Alpha-Chlorprothixene"@en .